Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18134044 | 0.82 | HPGD (0.64) | MAPTALDH1A1MAPK1HTTMEN1 | |
| SCHEMBL10360254 | 0.81 | HPGD (0.68) | MAPTALDH1A1CASP6GFERMAPK1 | |
| SCHEMBL27584378 | 0.81 | HPGD (0.41) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL5371361 | 0.80 | GFER (0.55) | MAPTALDH1A1CASP6GFERMEN1 | |
| SCHEMBL18131826 | 0.80 | GAA (0.52) | MAPTALDH1A1GFERHTTHPGD | |
| SCHEMBL5135273 | 0.80 | MAPT (0.55) | MAPTALDH1A1MAPK1HPGDLMNA | |
| SCHEMBL5058364 | 0.77 | MAPT (0.71) | MAPTALDH1A1CASP6GFERGPR174 | |
| SCHEMBL5074347 | 0.77 | HPGD (0.42) | MAPTALDH1A1MAPK1KMT2AHPGD | |
| SCHEMBL14432027 | 0.77 | HPGD (0.69) | MAPTALDH1A1GPR174MAPK1HTT | |
| SCHEMBL27584379 | 0.76 | HPGD (0.41) | MAPTALDH1A1MAPK1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312215-B2 | Benzimidazole C-2 heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312215-B2 | Benzimidazole C-2 heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312215-B2 | Benzimidazole C-2 heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7232826-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232826-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232826-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-19 | — | — | US | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7081454-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2006-07-25 | — | — | US | disclosed |
| EP-1651611-A2 | BENZIMIDAZOLE C-2 HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | WITTMAN MARK D | 2006-04-13 | — | — | US | disclosed |
| EP-1545543-A2 | NOVEL TYROSINE KINASES INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005021510-A2 | BENZIMIDAZOLE C-2 HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054655-A1 | Benzimidazole C-2 heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20040092514-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-13 | — | — | US | disclosed |
| WO-2004031401-A2 | NOVEL TYROSINE KINASES INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054655-A1 | Benzimidazole C-2 heterocycles as kinase inhibitors | CDK2, ERBB2, ABL1 | MAPT 4312/4885ALDH1A1 2026/4885CASP6 1798/4885 |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | ABL1, YES1, FER | MAPT 4113/4885ALDH1A1 1038/4885CASP6 2884/4885 |
| US-20040092514-A1 | Novel tyrosine kinase inhibitors | ABL1, ERBB2, ROS1 | MAPT 4085/4885ALDH1A1 1508/4885CASP6 2192/4885 |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | ABL1, FER, ERBB2 | MAPT 3720/4885ALDH1A1 1282/4885CASP6 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.